Eaton Vance Management’s VanEck Biotech ETF BBH Stock Holding History

Eaton Vance Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-305	Closed	-$57K	–	1886
2021 Q4	$57K	Hold	305	–	–	﹤0.01%	2042
2021 Q3	$52K	Hold	305	–	–	﹤0.01%	1514
2021 Q2	$61K	Hold	305	–	–	﹤0.01%	2083
2021 Q1	$54K	Buy	+305	New	+$55.2K	﹤0.01%	1773

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return

Eaton Vance Management's BBH Position: Q1 2022 in Review

Eaton Vance Management sold out of VanEck Biotech ETF (BBH) in Q1 2022, closing a stake of 305 shares — an estimated $57K sold.

Eaton Vance Management first reported a position in BBH in Q1 2021 and held it in 4 quarters. The position peaked at $61K in Q2 2021. 115 funds tracked by Wall St. Rank hold BBH as of Q1 2022.

Eaton Vance Management reported no remaining VanEck Biotech ETF position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 305 VanEck Biotech ETF shares in Q1 2022, an estimated $57K.
Eaton Vance Management first reported a position in VanEck Biotech ETF in Q1 2021 and held it in 4 quarters.
Eaton Vance Management's VanEck Biotech ETF position peaked at $61K in Q2 2021.
115 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.